Freed, E.Goldney, R.Lambert, T.Tiller, J.Johnston, R.2006-06-232006-06-231999Australian and New Zealand Journal of Psychiatry, 1999; 33(3):416-4210004-86741440-1614http://hdl.handle.net/2440/6316<h4>Objective</h4>This study compared the tolerability and efficacy of paroxetine and amitriptyline in the treatment of depression in general practice.<h4>Methods</h4>In this double-blind, multicentre study conducted in the general practice, patients with depression (Montgomery Asberg Depression Rating Scale [MADRS] score > or = 20) who were regarded as requiring antidepressant therapy were randomly assigned to receive paroxetine (20 mg, n = 184) or amitriptyline (50-100 mg, n = 191) once daily for 9 weeks.<h4>Results</h4>More patients completed treatment with paroxetine than with amitriptyline (71.1% vs 56.1%, p = 0.009). Depression rating scores (MADRS and Clinical Global Impression [CGI]) were improved with both agents, but at week 9, paroxetine achieved more favourable scores compared with amitriptyline on MADRS (p=0.019), CGI severity of depression (p=0.044), and CGI efficacy index (p = 0.038).<h4>Conclusions</h4>Depressed patients treated in general practice respond more quickly and are more likely to complete the treatment regimen with paroxetine than with amitriptyline.enHumansParoxetineAmitriptylineAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicTreatment OutcomeDrug Administration ScheduleChi-Square DistributionDouble-Blind MethodDepressive DisorderTime FactorsAdultAgedAged, 80 and overMiddle AgedPrimary Health CareAustraliaFemaleMaleSelective Serotonin Reuptake InhibitorsJournal article0030005991001999054510.1046/j.1440-1614.1999.00565.x2-s2.0-003299831169997